Cargando…

Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation

Detalles Bibliográficos
Autor principal:	Levi, Marcel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Federation of Internal Medicine. Published by Elsevier B.V. 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229910/ https://www.ncbi.nlm.nih.gov/pubmed/32425364 http://dx.doi.org/10.1016/j.ejim.2020.05.018

Ejemplares similares

Tocilizumab in severe COVID-19: A promise fulfilled
por: Levi, Marcel
Publicado: (2022)

The inflammation–coagulation axis as an important intermediate pathway in acute lung injury
por: Levi, Marcel, et al.
Publicado: (2008)

Tocilizumab is recommended for the treatment of severe COVID-19
por: Zhou, Yonggang, et al.
Publicado: (2020)

Why tocilizumab could be an effective treatment for severe COVID-19?
por: Fu, Binqing, et al.
Publicado: (2020)

Another step in improving the diagnosis of disseminated intravascular coagulation in sepsis
por: Levi, Marcel
Publicado: (2013)

Coagulation in sepsis: all bugs bite equally
por: Levi, Marcel, et al.
Publicado: (2004)

Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19
por: Di Nisio, Marcello, et al.
Publicado: (2021)

Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia
por: Agirbasli, Mehmet, et al.
Publicado: (2021)

Coagulation profile in severe COVID-19 patients: what do we know so far?
por: Savioli, Felicio, et al.
Publicado: (2020)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

COVID-19 coagulopathy: is it disseminated intravascular coagulation?
por: Levi, Marcel, et al.
Publicado: (2020)

COVID-19 coagulopathy vs disseminated intravascular coagulation
por: Levi, Marcel
Publicado: (2020)

Dysfunctional Coagulation in COVID-19: From Cell to Bedside
por: Wang, Jie, et al.
Publicado: (2020)

Single-dose tocilizumab blunts systemic inflammation in severe COVID-19 patients
por: de Roquetaillade, Charles, et al.
Publicado: (2022)

Tocilizumab as a promising agent against COVID-19: Issues and challenges
por: Dastan, Farzaneh, et al.
Publicado: (2021)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Coagulation abnormalities and thrombosis in patients with COVID-19
por: Levi, Marcel, et al.
Publicado: (2020)

Tocilizumab versus the Covid19 tempest: All’s well that ends well or much ado about nothing?
por: Lee, Todd C., et al.
Publicado: (2021)

Protease-activated receptor-1: key player in the sepsis coagulation-inflammation crosstalk
por: Asehnoune, Karim, et al.
Publicado: (2013)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

Properdin (factor P) as a new target cleaved by factor XIa: Intrinsic coagulation at the crossroads with inflammation
por: Luo, Qi, et al.
Publicado: (2022)

Fulfilling the promise of digital health interventions (DHI) to promote women’s sexual, reproductive and mental health in the aftermath of COVID-19
por: Chattu, Vijay Kumar, et al.
Publicado: (2021)

Budesonide: A promising candidate therapeutic for early COVID-19
por: Patel, Shailesh Kumar, et al.
Publicado: (2021)

Inflammation characteristics and anti-inflammation treatment with tocilizumab of severe/critical COVID-19 patients: A retrospective cohort study
por: Hu, Qin, et al.
Publicado: (2021)

Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
por: Gualtierotti, Roberta, et al.
Publicado: (2019)

Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls
por: Venkatesulu, Bhanu P, et al.
Publicado: (2020)

Impact of tocilizumab administration on mortality in severe COVID-19
por: Tsai, Andrew, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Effective treatment of severe COVID-19 patients with tocilizumab
por: Xu, Xiaoling, et al.
Publicado: (2020)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients
por: Wang, Yong, et al.
Publicado: (2022)

Predictors of Mortality in Tocilizumab-Treated Severe COVID-19
por: Pagkratis, Konstantinos, et al.
Publicado: (2022)

Management of coagulation disorders in severe inflammation
por: Lassila, Riitta, et al.
Publicado: (2019)

Exercise as a promising intervention in head & neck cancer patients
por: McNeely, M.L.
Publicado: (2013)

Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
por: Hong, Jin Yeong, et al.
Publicado: (2022)

From Panic to Promise: Harnessing Medical Student Leadership in COVID-19
por: Raikhel, A. Vincent, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v73r5n0kfid1sl4u5bathvpeei